Rubius Therapeutics, Inc. RUBY
Set alert
0.06 USD 0.00 0.00%
As of Dec 29, 3:49 PM ET
0.055 Day range 0.057
0.0032 52-week range 0.3763
- Open
- 0.0555
- Prev close
- 0.057
- Mkt cap
- 0
- Vol
- 755.86K
- Avg vol
- 99.53K
- EPS
- -1.99
- P/E
- -0.03
- Div yield
- 0.00%
More statistics
- Low
- 0.055
- High
- 0.057
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 3, 2024
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Jan 3, 2024
Expected Jan 3, 2024. Consensus EPS estimate 0.00.
Financials — quick view
RUBY Revenue — quarterly 0
RUBY Net income — quarterly -20.14M
RUBY EPS — quarterly -0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 3, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | -0.42 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -0.52 | — | — | — |
News
- SEABOURN UNVEILS DETAILS OF 'THE RUBY COLLECTION': 54 VOYAGES ACROSS OCEAN AND EXPEDITION FOR ITS 40TH ANNIVERSARY IN 2028
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Friday
- Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on RUBY — it syncs with the Stock Master app.